StreetInsider.com News Articles

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

Mon, 27 Jul 2026 08:30:00 -0400

CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.

The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

Mon, 27 Jul 2026 08:30:00 -0400

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Collard Craig A

Mon, 20 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260720/26789971.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Collard Craig A

Mon, 20 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260720/26789971.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Forbes William P

Mon, 20 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260720/26789810.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Forbes William P

Mon, 20 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260720/26789810.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Duarte Ira

Mon, 20 Jul 2026 15:54:00 -0400

si-local-file:///var/storage/secattach/20260720/26789576.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Duarte Ira

Mon, 20 Jul 2026 15:54:00 -0400

si-local-file:///var/storage/secattach/20260720/26789576.html

Form 8-K HERON THERAPEUTICS, INC. For: Jun 25

Thu, 25 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260625/26693262.html

Form 8-K HERON THERAPEUTICS, INC. For: Jun 25

Thu, 25 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260625/26693262.html

Form 4 HERON THERAPEUTICS, INC. For: Jun 16 Filed by: Duarte Ira

Wed, 17 Jun 2026 10:52:00 -0400

si-local-file:///var/storage/secattach/20260617/26658333.html

Form 4 HERON THERAPEUTICS, INC. For: Jun 16 Filed by: Duarte Ira

Wed, 17 Jun 2026 10:52:00 -0400

si-local-file:///var/storage/secattach/20260617/26658333.html

Form 8-K HERON THERAPEUTICS, INC. For: Jun 11

Tue, 16 Jun 2026 14:49:00 -0400

si-local-file:///var/storage/secattach/20260616/26653578.html

Form 8-K HERON THERAPEUTICS, INC. For: Jun 11

Tue, 16 Jun 2026 14:49:00 -0400

si-local-file:///var/storage/secattach/20260616/26653578.html

Form 4 HERON THERAPEUTICS, INC. For: Jun 06 Filed by: Forbes William P

Mon, 08 Jun 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260608/26615666.html

Form 4 HERON THERAPEUTICS, INC. For: Jun 06 Filed by: Forbes William P

Mon, 08 Jun 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260608/26615666.html

Heron Therapeutics (HRTX) PT Lowered to $2 at H.C. Wainwright

Wed, 03 Jun 2026 06:22:31 -0400

H.C. Wainwright analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $2.00 (from $4.00) while maintaining a Buy rating.

Form 8-K HERON THERAPEUTICS, INC. For: Jun 02

Tue, 02 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260602/26593197.html

Form 8-K HERON THERAPEUTICS, INC. For: Jun 02

Tue, 02 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260602/26593197.html

Needham Downgrades Heron Therapeutics (HRTX) to Hold

Tue, 02 Jun 2026 16:00:26 -0400

Needham analyst Serge Belanger downgraded Heron Therapeutics (NASDAQ: HRTX) from Buy to Hold.

For an analyst ratings summary and ratings history on Heron Therapeutics click here. For more ratings news on Heron Therapeutics click here.

Shares of Heron Therapeutics closed at $0.83 yesterday.

Heron Therapeutics loses patent case for CINVANTI drug

Tue, 02 Jun 2026 08:12:51 -0400

Heron Therapeutics, Inc. (NASDAQ: HRTX) announced that the U.S. District Court for the District of Delaware ruled against the company in patent litigation with Azurity Pharmaceuticals regarding CINVANTI (aprepitant) injectable emulsion. The court held that claims in Heron's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.

The decision does not affect any existing settlement agreements related to CINVANTI or APONVIE (aprepitant) injectable emulsion. Heron plans to appeal the ruling to the United States Court of Appeals for the Federal Circuit.

"We are disappointed with this initial result of the litigation and will vigorously pursue our appeal and all available remedies, including equitable

Heron Therapeutics loses patent case for CINVANTI drug

Tue, 02 Jun 2026 08:12:51 -0400

"We are disappointed with this initial result of the litigation and will vigorously pursue our appeal and all available remedies, including equitable

U.S. District Court Issues Decision Regarding CINVANTI® Patents

Tue, 02 Jun 2026 08:12:00 -0400

CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company’s U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid. This decision has no impact on any prior settlement agreement related to CINVANTI® (aprepitant) injectable

U.S. District Court Issues Decision Regarding CINVANTI® Patents

Tue, 02 Jun 2026 08:12:00 -0400

U.S. District Court Issues Decision Regarding CINVANTI® Patents

Tue, 02 Jun 2026 08:12:00 -0400